which defined moderate-tosevere disease as a body surface area of â‰¥5% meeting to ensure that patient input was incorporated into the final PsA guideline. Examples of patient feedback included strong value on therapies that are effective (e.g., prevent further damage, and improve quality of life, social participation, and function) and safe (especially having low adverse event profiles). In particular, patients discussed the negative impact of adverse events (e.g., fatigue, nausea, and malaise)